New approaches to influenza chemotherapy. Neuraminidase inhibitors

Drugs

Volumn 56, Issue 4, 1998, Pages 537-553

  Calfee, D P ^a   Hayden, F G ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ETHYL 4 ACETAMIDO 5 AZIDO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLATE PHOSPHATE; INFLUENZA VACCINE; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR;

AEROSOL; ANTIGENIC VARIATION; AQUEOUS SOLUTION; CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRY POWDER; ENZYME INHIBITION; HEADACHE; HIGH RISK PATIENT; HUMAN; INFLUENZA; INFLUENZA VIRUS B; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; META ANALYSIS; MORBIDITY; MORTALITY; NAUSEA; REVIEW; VIRUS RESISTANCE;

ANIMALIA; INFLUENZA VIRUS; INFLUENZAVIRUS B;

EID: 0031767836     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856040-00003     Document Type: Review

References (63)

1. 1. PM Colman JN Varghese WG Laver 1983 Structure of the catalytic and antigenic sites in influenza virus neuraminidase Nature 303 5912 41 4 6188957 10.1038/303041a0 1:CAS:528:DyaL3sXktVeqsrw%3D Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303(5912): 41–4
2. 2. M Itzstein von WY Wu GB Kok 1993 Rational design of potent sialidase-based inhibitors of influenza virus replication Nature 363 6428 418 23 10.1038/363418a0 von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363(6428): 418–23
3. 3. PM Colman 1994 Influenza virus neuraminidase: structure, antibodies, and inhibitors Protein Sci 3 10 1687 96 7849585 10.1002/pro.5560031007 1:CAS:528:DyaK2MXit1yjs78%3D Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 1994; 3(10): 1687–96
4. 4. S Schultz-Cherry VS Hinshaw 1996 Influenza virus neuraminidase activates latent transforming growth factor beta J Virol 70 12 8624 9 8970987 1:CAS:528:DyaK28XmvVGmu74%3D Schultz-Cherry S, Hinshaw VS. Influenza virus neuraminidase activates latent transforming growth factor beta. J Virol 1996; 70(12): 8624–9
5. 5. M Houde DJ Arora 1990 Stimulation of tumor necrosis factor secretion by purified influenza virus neuraminidase Cell Immunol 129 1 104 11 2364437 10.1016/0008-8749(90)90190-3 1:CAS:528:DyaK3cXkslKhurw%3D Houde M, Arora DJ. Stimulation of tumor necrosis factor secretion by purified influenza virus neuraminidase. Cell Immunol 1990; 129(1): 104–11
6. 6. BR Murphy JA Kasel RM Chanock 1972 Association of serum anti-neuraminidase antibody with resistance to influenza in man N Engl J Med 286 25 1329 32 5027388 10.1056/NEJM197206222862502 1:STN:280:DyaE387oslKgug%3D%3D Murphy BR, Kasel JA, Chanock RM. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972; 286(25): 1329–32
7. 7. AS Monto AP Kendal 1973 Effect of neuraminidase antibody on Hong Kong influenza Lancet 1 7804 623 5 4121842 10.1016/S0140-6736(73)92196-X 1:STN:280:DyaE3s7ntVKisQ%3D%3D Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1973; 1(7804): 623–5
8. 8. RB Couch JA Kasel JL Gerin 1974 Induction of partial immunity to influenza by a neuraminidase-specific vaccine J Infect Dis 129 4 411 20 4593871 10.1093/infdis/129.4.411 1:STN:280:DyaE2c7isFSrtQ%3D%3D Couch RB, Kasel JA, Gerin JL, et al. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 1974; 129(4): 411–20
9. 9. KR Beutner T Chow E Rubi 1979 Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection J Infect Dis 140 6 844 50 396336 10.1093/infdis/140.6.844 1:STN:280:DyaL3c7mtFartA%3D%3D Beutner KR, Chow T, Rubi E, et al. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J Infect Dis 1979; 140(6): 844–50
10. 10. RG Webster PA Reay WG Laver 1988 Protection against lethal influenza with neuraminidase Virology 164 1 230 7 2452514 10.1016/0042-6822(88)90640-X 1:CAS:528:DyaL1cXit1Sjs7s%3D Webster RG, Reay PA, Laver WG. Protection against lethal influenza with neuraminidase. Virology 1988; 164(1): 230–7
11. 11. P Meindl H Tuppy 1969 2-deoxy-2,3-dehydroxialic acids I Syntheses and properties of 2-deoxy,3dehydro-N-acylneuraminic acids and their methyl esters. Monatsc Chem 100 1295 2306 1:CAS:528:DyaF1MXltFehs78%3D Meindl P, Tuppy H. 2-deoxy-2,3-dehydroxialic acids I. Syntheses and properties of 2-deoxy,3dehydro-N-acylneuraminic acids and their methyl esters. Monatsc Chem 1969; 100: 1295–2306
12. 12. P Meindl G Bodo P Palese 1974 Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetyl-neuraminic acid Virology 58 2 457 63 4362431 10.1016/0042-6822(74)90080-4 1:CAS:528:DyaE2cXhsVagsrg%3D Meindl P, Bodo G, Palese P, et al. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetyl-neuraminic acid. Virology 1974; 58(2): 457–63
13. 13. JN Varghese VC Epa PM Colman 1995 Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase Protein Sci 4 6 1081 7 7549872 10.1002/pro.5560040606 1:CAS:528:DyaK2MXmsFyrs7o%3D Varghese JN, Epa VC, Colman PM. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci 1995; 4(6): 1081–7
14. 14. MS Pegg M Itzstein von 1994 Slow-binding inhibition of sialidase from influenza virus Biochem Mol Biol Int 32 5 851 8 8069234 1:CAS:528:DyaK2cXlvF2hsr4%3D Pegg MS, von Itzstein M. Slow-binding inhibition of sialidase from influenza virus. Biochem Mol Biol Int 1994; 32(5): 851–8
15. 15. GJ Hart RC Bethell 1995 2,3-didehydro-2,4-dideoxy-4-guanidino-N-acetyl-D-neuraminic acid (4-guanidino-Neu5Ac2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus Biochem Mol Biol Int 36 4 695 703 8528132 1:CAS:528:DyaK28Xjtl2hs7g%3D Hart GJ, Bethell RC. 2,3-didehydro-2,4-dideoxy-4-guanidino-N-acetyl-D-neuraminic acid (4-guanidino-Neu5Ac2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus. Biochem Mol Biol Int 1995; 36(4): 695–703
16. 16. JM Woods RC Bethell JA Coates 1993 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in. vitro Antimicrob Agents Chemother 37 7 1473 9 8363379 10.1128/AAC.37.7.1473 1:CAS:528:DyaK3sXlsFKjtr4%3D Woods JM, Bethell RC, Coates JA, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in. vitro. Antimicrob Agents Chemother 1993; 37(7): 1473–9
17. 17. GP Thomas M Forsyth CR Penn 1994 Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid Antiviral Res 24 4 351 6 7993078 10.1016/0166-3542(94)90081-7 1:CAS:528:DyaK2cXmsVGiu7s%3D Thomas GP, Forsyth M, Penn CR, et al. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. Antiviral Res 1994; 24(4): 351–6
18. 18. LV Gubareva CR Penn RG Webster 1995 Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid Virology 212 2 323 30 7571401 10.1006/viro.1995.1489 1:CAS:528:DyaK2MXosFWgsLo%3D Gubareva LV, Penn CR, Webster RG. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 1995; 212(2): 323–30
19. 19. FG Hayden BS Rollins LK Madren 1994 Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium [erratum in Antiviral Res 1994 Dec; 25 (3–4): 287] Antiviral Res 25 2 123 31 7847874 10.1016/0166-3542(94)90101-5 1:CAS:528:DyaK2cXmslWgu70%3D Hayden FG, Rollins BS, Madren LK. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium [erratum in Antiviral Res 1994 Dec; 25 (3–4): 287]. Antiviral Res 1994; 25(2): 123–31
20. 20. DM Ryan J Ticehurst MH Dempsey 1994 Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase) Antimicrob Agents Chemother 38 10 2270 5 7840556 10.1128/AAC.38.10.2270 1:CAS:528:DyaK2cXmsVGht7o%3D Ryan DM, Ticehurst J, Dempsey MH, et al. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 1994; 38(10): 2270–5
21. 21. DM Ryan J Ticehurst MH Dempsey 1995 GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets Antimicrob Agents Chemother 39 11 2583 4 8585752 10.1128/AAC.39.11.2583 1:CAS:528:DyaK2MXptFylsbY%3D Ryan DM, Ticehurst J, Dempsey MH. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother 1995; 39(11): 2583–4
22. 22. GG167 Clinical investigator’s brochure. 3-97. Greenford, Middlesex, England: Glaxo Wellcome Research and Development Ltd., March 1997
23. 23. JW McCauley LA Pullen M Forsyth 1995 4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus Antiviral Res 27 1–2 179 86 7486955 10.1016/0166-3542(95)00005-7 1:CAS:528:DyaK2MXlsFCjuro%3D McCauley JW, Pullen LA, Forsyth M, et al. 4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus. Antiviral Res 1995; 27(1–2): 179–86
24. 24. RW Sidwell JH Huffman DL Barnard 1998 Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor Antiviral Res 37 107 20 9588843 10.1016/S0166-3542(97)00065-X 1:CAS:528:DyaK1cXhvVSjsbs%3D Sidwell RW, Huffman JH, Barnard DL, et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 1998; 37: 107–20
25. 25. Efthymiopoulos C, Barrington P, Patel JA. Pharmacokinetics of the neuraminidase inhibitor 4-guanidino Neu5Ac2en (GG167) following intravenous, intranasal, and inhaled administration in man [abstract no. H70]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society of Microbiology; 1994 Oct 4–7; Orlando (FL), 265
26. 26. Newman SP, Brown J, Pickford M, et al. Deposition pattern in the respiratory tract of the neuraminidase inhibitor zanamivir; a gamma scintigraphic study [abstract no. H-134]. 37th Inter-science Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto (ON), 237
27. 27. FG Hayden JJ Treanor RF Betts 1996 Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza JAMA 275 4 295 9 8544269 10.1001/jama.1996.03530280047035 1:CAS:528:DyaK28Xhtl2rsbc%3D Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275(4): 295–9
28. 28. JB Walker EK Hussey JJ Treanor 1997 Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza J Infect Dis 176 1417 22 9395349 10.1086/514136 1:CAS:528:DyaK2sXnslOrtrc%3D Walker JB, Hussey EK, Treanor JJ, et al. Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza. J Infect Dis 1997; 176: 1417–22
29. 29. FG Hayden M Lobo EK Hussey 1996 Efficacy of intranasal GG167 in experimental human influenza A and B virus infection LE Brown AW Hampson RG Webster Options for the control of influenza III Elsevier Science B.V Amsterdam 718 25 Hayden FG, Lobo M, Hussey EK, et al. Efficacy of intranasal GG167 in experimental human influenza A and B virus infection. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III. Amsterdam: Elsevier Science B.V, 1996: 718–25
30. 30. FG Hayden ADME Osterhaus JJ Treanor 1997 Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections N Engl J Med 337 13 874 9 9302301 10.1056/NEJM199709253371302 1:CAS:528:DyaK2sXmtlylur8%3D Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337(13): 874–9
31. 31. K Matsumoto K Nerome Y Numasaki 1996 Inhaled and intranasal GG167 in the treatment of influenza A and B: preliminary results LE Brown AW Hampson RG Webster Options for the control of influenza III Elsevier Science Amsterdam 713 7 Matsumoto K, Nerome K, Numasaki Y. Inhaled and intranasal GG167 in the treatment of influenza A and B: preliminary results. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III. Amsterdam: Elsevier Science; 1996: 713–7
32. 32. Aoki FY, Fleming DM, Lacey L, et al. Impact of treatment of influenza with zanamivir on patients’ health status, sleep quality, productivity and healthcare use [abstract no. N-15]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto (ON), 384
33. 33. Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir of chemoprophylaxis of nursing home influenza A outbreaks [abstract no. H-92]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto (ON), 230
34. 34. CU Kim W Lew MA Williams 1997 Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity J Am Chem Soc 119 681 90 16526129 10.1021/ja963036t 1:CAS:528:DyaK2sXitFWjuw%3D%3D Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997; 119: 681–90
35. 35. FG Hayden BS Rollins 1997 In vitro activity of the neuraminidase inhibitor GS4071 against influenza viruses [abstract no. 159] Antiviral Res 34 A86 Hayden FG, Rollins BS. In vitro activity of the neuraminidase inhibitor GS4071 against influenza viruses [abstract no. 159]. Antiviral Res 1997; 34: A86
36. 36. DB Mendel CY Tai PA Escarpe 1998 Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection Antimicrob Agents Chemother 42 3 640 6 9517945 1:CAS:528:DyaK1cXhvV2ktb4%3D Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998; 42(3): 640–6
37. 37. W Li PA Escarpe EJ Eisenberg 1998 Identification of GS4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS4071 Antimicrob Agents Chemother 42 3 647 53 9517946 1:CAS:528:DyaK1cXhvV2ktb8%3D Li W, Escarpe PA, Eisenberg EJ, et al. Identification of GS4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS4071. Antimicrob Agents Chemother 1998; 42(3): 647–53
38. 38. Cundy K, Eisenberg G, Bidgood A, et al. The novel influenza neuraminidase inhibitor prodrug GS4104 is highly bioavailable in animals [abstract H-135]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto (ON), 237
39. 39. G Eisenberg A Bidgood G Lynch 1997 Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104 Antimicrob Agents Chemother 41 1949 52 9303391 1:CAS:528:DyaK2sXlvFOgtbk%3D Eisenberg G, Bidgood A, Lynch G, et al. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Agents Chemother 1997; 41: 1949–52
40. 40. Investigational drug brochure: Ro64-0796. 2-1997. Gilead-Sciencs and F Hoffman-La Roche Ltd: 1–26 (Data on file)
41. 41. RJ Fenton PJ Morley IJ Owens 1998 Activities of zanamivir (GG167) and GS4104 in a series of influenza A virus animal models [abstract no. 173] Antiviral Res 37 A88 Fenton RJ, Morley PJ, Owens IJ, et al. Activities of zanamivir (GG167) and GS4104 in a series of influenza A virus animal models [abstract no. 173]. Antiviral Res 1998; 37: A88
42. 42. Wood ND, Aitken M, Sharp S, et al. Tolerability and pharmacokinetics of the influenza neuraminidase inhibitor Ro-64-0802 (GS4071) following oral administration of the prodrug Ro-64-0796 (GS4104) to healthy male volunteers [abstract no. A-123]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto (ON), 25
43. 43. Hayden FG, Lobo M, Treanor JJ, et al. Efficacy and tolerability of oral GS4104 for early treatment of experimental influenza in humans [abstract no. LB-26]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto (ON), 14
44. 44. Barnett J, Dempsey M, Rothbarth PH, et al. Susceptibility monitoring of influenza virus clinical isolates to the neuraminidase inhibitor zanamivir (GG167) during phase II clinical efficacy trials [abstract no. H-93]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto (ON), 230
45. 45. JL McKimm-Breschkin TJ Blick 1996 Sahasrabudhe A. Influenza virus variants with decreased sensitivity to 4-amino-and 4-guanidino-Neu5Ac2en LE Brown AW Hampson RG Webster Options for the control of influenza III Elsevier Science Amsterdam 726 34 McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A. Influenza virus variants with decreased sensitivity to 4-amino-and 4-guanidino-Neu5Ac2en. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III. Amsterdam: Elsevier Science; 1996: 726–34
46. 46. JL McKimm-Breschkin TJ Blick A Sahasrabudhe 1996 Generation and characterization of variants of NWS/G70C influenza virus after in. vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 40 1 40 6 8787876 1:CAS:528:DyaK28XhvFKqtQ%3D%3D McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, et al. Generation and characterization of variants of NWS/G70C influenza virus after in. vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 1996; 40(1): 40–6
47. 47. CR Penn J Barnett R Bethell 1996 Selection of influenza virus with reduced sensitivity in vitro to the neuraminidase inhibitor GG167 (4-guanidino-Neu5Ac2en): changes in haemagglutinin may compensate for loss of neuraminidase activity LE Brown AW Hampson RG Webster Options for the control of influenza III Elsevier Science B.V. Amsterdam 735 40 Penn CR, Barnett J, Bethell R, et al. Selection of influenza virus with reduced sensitivity in vitro to the neuraminidase inhibitor GG167 (4-guanidino-Neu5Ac2en): changes in haemagglutinin may compensate for loss of neuraminidase activity. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III. Amsterdam, Elsevier Science B.V.; 1996:735–40
48. 48. TJ Blick T Tiong A Sahasrabudhe 1995 Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en Virology 214 2 475 84 8553549 10.1006/viro.1995.0058 1:CAS:528:DyaK28XislygsA%3D%3D Blick TJ, Tiong T, Sahasrabudhe A, et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 1995; 214(2): 475–84
49. 49. KA Staschke JM Colacino AJ Baxter 1995 Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en Virology 214 2 642 6 8553569 10.1006/viro.1995.0078 1:CAS:528:DyaK28XislymsA%3D%3D Staschke KA, Colacino JM, Baxter AJ, et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 1995; 214(2): 642–6
50. 50. LV Gubareva R Bethell GJ Hart 1996 Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en J Virol 70 3 1818 27 8627706 1:CAS:528:DyaK28XpvFaksA%3D%3D Gubareva LV, Bethell R, Hart GJ, et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996; 70(3): 1818–27
51. 51. LV Gubareva MJ Robinson RC Bethell 1997 Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en J Virol 71 5 3385 90 9094607 1:CAS:528:DyaK2sXisFWgtL0%3D Gubareva LV, Robinson MJ, Bethell RC, et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71(5): 3385–90
52. 52. LV Gubareva R Bethell CR Penn 1996 In vitro characterization of 4-guanidino-Neu5Ac2en-resistant mutants of influenza A virus LE Brown AW Hampson RG Webster Options for the control of influenza III Elsevier Science Amsterdam 753 60 Gubareva LV, Bethell R, Penn CR, et al. In vitro characterization of 4-guanidino-Neu5Ac2en-resistant mutants of influenza A virus. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III. Amsterdam, Elsevier Science; 1996: 753–60
53. 53. JL McKimm-Breschkin A Sahasrabudhe TJ Blick 1998 Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors J Virol 72 3 2456 62 9499107 1:CAS:528:DyaK1cXhtFegtrk%3D McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998; 72(3): 2456–62
54. 54. Sahasrabudhe A, Blick TJ, McKimm-Breschkin JL. Influenza virus variants resistant to GG167 with mutations in the hemagglutinin. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III. Amsterdam: Elsevier Science; 1996: 748–52
55. 55. Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. In press
56. 56. M Itzstein von JC Dyason SW Oliver 1996 A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs J Med Chem 39 2 388 91 10.1021/jm950294c von Itzstein M, Dyason JC, Oliver SW, et al. A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. J Med Chem 1996; 19; 39(2): 388–91
57. 57. CL White MN Janakiraman WG Laver 1995 A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies J Mol Biol 245 5 623 34 7844831 10.1006/jmbi.1994.0051 1:CAS:528:DyaK2MXjsFOntLs%3D White CL, Janakiraman MN, Laver WG, et al. A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies. J Mol Biol 1995; 245(5): 623–34
58. 58. S Singh MJ Jedrzejas GM Air 1995 Structure-based inhibitors of influenza virus sialidase: a benzoic acid lead with novel interaction J Med Chem 38 17 3217 25 7650674 10.1021/jm00017a005 1:CAS:528:DyaK2MXnt1KmsLw%3D Singh S, Jedrzejas MJ, Air GM, et al. Structure-based inhibitors of influenza virus sialidase: a benzoic acid lead with novel interaction. J Med Chem 1995; 38(17): 3217–25
59. 59. M Murakami K Ikeda K Achiwa 1996 Chemoenzymatic synthesis of neuraminic acid analogs structurally varied at C-5 and C-9 as potential inhibitors of the sialidase from influenza virus Carbohydr Res 280 1 101 10 8581891 10.1016/0008-6215(95)00295-2 1:CAS:528:DyaK28XhsVGqsQ%3D%3D Murakami M, Ikeda K, Achiwa K. Chemoenzymatic synthesis of neuraminic acid analogs structurally varied at C-5 and C-9 as potential inhibitors of the sialidase from influenza virus. Carbohydr Res 1996; 280(1): 101–10
60. 60. S Sollis PW Smith PD Howes 1996 Novel inhibitors of influenza sialidase related to GG167._Synthesis of 4-amino and guanidino-4H-pyran-2-carboxylic acid-6-propylamides; selective inhibitors of influenza virus sialidase Bioorg Med Chem 6 1805 8 10.1016/0960-894X(96)00318-6 1:CAS:528:DyaK28XltFWrtb8%3D Sollis S, Smith PW, Howes PD. Novel inhibitors of influenza sialidase related to GG167._Synthesis of 4-amino and guanidino-4H-pyran-2-carboxylic acid-6-propylamides; selective inhibitors of influenza virus sialidase. Bioorg Med Chem 1996; 6: 1805–8
61. 61. B Barrere PA Driguez J Maudrin 1997 A novel synthetic reversible inhibitor of sialidase efficiently blocks secondary but not primary influenza virus infection of MDCK cells in culture Arch Virol 142 7 1365 80 9267449 10.1007/s007050050166 1:CAS:528:DyaK2sXls1ymtr0%3D Barrere B, Driguez PA, Maudrin J, et al. A novel synthetic reversible inhibitor of sialidase efficiently blocks secondary but not primary influenza virus infection of MDCK cells in culture. Arch Virol 1997; 142(7): 1365–80
62. 62. T Nagai R Moriguchi Y Suzuki 1995 Mode of action of the anti-influenza virus activity of plant flavonoid, 5,7,4′-trihydroxy-8-methoxyflavone, from the roots of Scutellaria baicalensis Antiviral Res 26 1 11 25 7741518 10.1016/0166-3542(94)00062-D 1:CAS:528:DyaK2MXjs1Clsrc%3D Nagai T, Moriguchi R, Suzuki Y, et al. Mode of action of the anti-influenza virus activity of plant flavonoid, 5,7,4′-trihydroxy-8-methoxyflavone, from the roots of Scutellaria baicalensis. Antiviral Res 1995; 26(1): 11–25
63. 63. T Nagai Y Miyaichi T Tomimori 1992 In vivo anti-influenza virus activity of plant flavonoids possessing inhibitory activity for influenza virus sialidase Antiviral Res 19 3 207 17 1444327 10.1016/0166-3542(92)90080-O 1:CAS:528:DyaK3sXjt1Glsg%3D%3D Nagai T, Miyaichi Y, Tomimori T, et al. In vivo anti-influenza virus activity of plant flavonoids possessing inhibitory activity for influenza virus sialidase. Antiviral Res 1992; 19(3): 207–17